These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 33059828)

  • 1. Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial.
    Pibarot P; Ternacle J; Jaber WA; Salaun E; Dahou A; Asch FM; Weissman NJ; Rodriguez L; Xu K; Annabi MS; Guzzetti E; Beaudoin J; Bernier M; Leipsic J; Blanke P; Clavel MA; Rogers E; Alu MC; Douglas PS; Makkar R; Miller DC; Kapadia SR; Mack MJ; Webb JG; Kodali SK; Smith CR; Herrmann HC; Thourani VH; Leon MB; Hahn RT;
    J Am Coll Cardiol; 2020 Oct; 76(16):1830-1843. PubMed ID: 33059828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients.
    Madhavan MV; Kodali SK; Thourani VH; Makkar R; Mack MJ; Kapadia S; Webb JG; Cohen DJ; Herrmann HC; Williams M; Greason K; Pibarot P; Hahn RT; Jaber W; Xu K; Alu M; Smith CR; Leon MB
    J Am Coll Cardiol; 2023 Jul; 82(2):109-123. PubMed ID: 37407110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk.
    Søndergaard L; Ihlemann N; Capodanno D; Jørgensen TH; Nissen H; Kjeldsen BJ; Chang Y; Steinbrüchel DA; Olsen PS; Petronio AS; Thyregod HGH
    J Am Coll Cardiol; 2019 Feb; 73(5):546-553. PubMed ID: 30732707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Year Outcomes Comparing Surgical Versus Transcatheter Aortic Valve Replacement in Patients With Chronic Kidney Disease.
    Garcia S; Cubeddu RJ; Hahn RT; Ternacle J; Kapadia SR; Kodali SK; Thourani VH; Jaber WA; Asher CR; Elmariah S; Makkar R; Webb JG; Herrmann HC; Lu M; Devireddy CM; Malaisrie SC; Smith CR; Mack MJ; Sorajja P; Cavalcante JL; Goessl M; Shroff GR; Leon MB; Pibarot P
    JACC Cardiovasc Interv; 2021 Sep; 14(18):1995-2005. PubMed ID: 34556273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of SAPIEN 3 Transcatheter Valve Implantation on Health Status in Patients With Severe Aortic Stenosis at Intermediate Surgical Risk: Results From the PARTNER S3i Trial.
    Baron SJ; Thourani VH; Kodali S; Arnold SV; Wang K; Magnuson EA; Pichard AD; Babaliaros V; George I; Miller DC; Tuzcu EM; Greason K; Herrmann HC; Smith CR; Leon MB; Cohen DJ;
    JACC Cardiovasc Interv; 2018 Jun; 11(12):1188-1198. PubMed ID: 29860075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioprosthetic structural valve deterioration: How do TAVR and SAVR prostheses compare?
    Aldalati O; Kaura A; Khan H; Dworakowski R; Byrne J; Eskandari M; Deshpande R; Monaghan M; Wendler O; MacCarthy P
    Int J Cardiol; 2018 Oct; 268():170-175. PubMed ID: 30041783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk.
    Baron SJ; Wang K; House JA; Magnuson EA; Reynolds MR; Makkar R; Herrmann HC; Kodali S; Thourani VH; Kapadia S; Svensson L; Mack MJ; Brown DL; Russo MJ; Smith CR; Webb J; Miller C; Leon MB; Cohen DJ
    Circulation; 2019 Feb; 139(7):877-888. PubMed ID: 30586747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial.
    Pibarot P; Salaun E; Dahou A; Avenatti E; Guzzetti E; Annabi MS; Toubal O; Bernier M; Beaudoin J; Ong G; Ternacle J; Krapf L; Thourani VH; Makkar R; Kodali SK; Russo M; Kapadia SR; Malaisrie SC; Cohen DJ; Leipsic J; Blanke P; Williams MR; McCabe JM; Brown DL; Babaliaros V; Goldman S; Szeto WY; Généreux P; Pershad A; Alu MC; Xu K; Rogers E; Webb JG; Smith CR; Mack MJ; Leon MB; Hahn RT;
    Circulation; 2020 May; 141(19):1527-1537. PubMed ID: 32272848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Hemodynamics of Transcatheter and Surgical Aortic Valves in the PARTNER Trial.
    Douglas PS; Leon MB; Mack MJ; Svensson LG; Webb JG; Hahn RT; Pibarot P; Weissman NJ; Miller DC; Kapadia S; Herrmann HC; Kodali SK; Makkar RR; Thourani VH; Lerakis S; Lowry AM; Rajeswaran J; Finn MT; Alu MC; Smith CR; Blackstone EH;
    JAMA Cardiol; 2017 Nov; 2(11):1197-1206. PubMed ID: 28973520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery.
    Webb JG; Doshi D; Mack MJ; Makkar R; Smith CR; Pichard AD; Kodali S; Kapadia S; Miller DC; Babaliaros V; Thourani V; Herrmann HC; Bodenhamer M; Whisenant BK; Ramee S; Maniar H; Kereiakes D; Xu K; Jaber WA; Menon V; Tuzcu EM; Wood D; Svensson LG; Leon MB
    JACC Cardiovasc Interv; 2015 Dec; 8(14):1797-806. PubMed ID: 26718510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients.
    Gleason TG; Reardon MJ; Popma JJ; Deeb GM; Yakubov SJ; Lee JS; Kleiman NS; Chetcuti S; Hermiller JB; Heiser J; Merhi W; Zorn GL; Tadros P; Robinson N; Petrossian G; Hughes GC; Harrison JK; Conte JV; Mumtaz M; Oh JK; Huang J; Adams DH;
    J Am Coll Cardiol; 2018 Dec; 72(22):2687-2696. PubMed ID: 30249462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mid-term outcomes of Sapien 3 versus Perimount Magna Ease for treatment of severe aortic stenosis.
    Virtanen MPO; Eskola M; Savontaus M; Juvonen T; Niemelä M; Laakso T; Husso A; Jalava MP; Tauriainen T; Ahvenvaara T; Maaranen P; Kinnunen EM; Dahlbacka S; Laine M; Mäkikallio T; Valtola A; Raivio P; Rosato S; D'Errigo P; Vento A; Airaksinen J; Biancari F
    J Cardiothorac Surg; 2020 Jun; 15(1):157. PubMed ID: 32600369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioprosthetic valve failure. Comparative trial of two balloon-expandable transcatheter heart valve systems in intermediate-risk patients: a propensity score analysis.
    Eid-Lidt G; Vega Servín S; Farjat Pasos JI; Rivera Rodríguez A; Anaya Morales CA; Marroquin Donday LA; Nombela Franco L; Gaspar J
    Acta Cardiol; 2022 Apr; 77(2):158-165. PubMed ID: 34092183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten year follow-up of high-risk patients treated during the early experience with transcatheter aortic valve replacement.
    Sathananthan J; Lauck S; Polderman J; Yu M; Stephenson A; Sathananthan G; Moss R; Cheung A; Ye J; Blanke P; Leipsic J; Wood DA; Webb JG
    Catheter Cardiovasc Interv; 2021 Feb; 97(3):E431-E437. PubMed ID: 32940418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial.
    Thyregod HGH; Jørgensen TH; Ihlemann N; Steinbrüchel DA; Nissen H; Kjeldsen BJ; Petursson P; De Backer O; Olsen PS; Søndergaard L
    Eur Heart J; 2024 Apr; 45(13):1116-1124. PubMed ID: 38321820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis.
    Thourani VH; Kodali S; Makkar RR; Herrmann HC; Williams M; Babaliaros V; Smalling R; Lim S; Malaisrie SC; Kapadia S; Szeto WY; Greason KL; Kereiakes D; Ailawadi G; Whisenant BK; Devireddy C; Leipsic J; Hahn RT; Pibarot P; Weissman NJ; Jaber WA; Cohen DJ; Suri R; Tuzcu EM; Svensson LG; Webb JG; Moses JW; Mack MJ; Miller DC; Smith CR; Alu MC; Parvataneni R; D'Agostino RB; Leon MB
    Lancet; 2016 May; 387(10034):2218-25. PubMed ID: 27053442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioprosthetic Valve Performance After Transcatheter Aortic Valve Replacement With Self-Expanding Versus Balloon-Expandable Valves in Large Versus Small Aortic Valve Annuli: Insights From the CHOICE Trial and the CHOICE-Extend Registry.
    Abdelghani M; Mankerious N; Allali A; Landt M; Kaur J; Sulimov DS; Merten C; Sachse S; Mehilli J; Neumann FJ; Frerker C; Kurz T; El-Mawardy M; Richardt G; Abdel-Wahab M
    JACC Cardiovasc Interv; 2018 Dec; 11(24):2507-2518. PubMed ID: 30503595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aortic Regurgitation, Time to Aortic Valve Reintervention, and Mortality in Degenerated Trifecta Versus Non-Trifecta Bioprosthesis.
    Abbas AE; Madanat L; Khalili H; Mando R; Kheyrbek M; Chandra R; Niroula S; Hanson I; Dixon S; Renard B; Bloomingdale R; Cami E; Pridham B; Altshuler J; Kindzelski B; Fazzalari F; Shannon F; Vivacqua A
    Am J Cardiol; 2024 Jun; 220():49-55. PubMed ID: 38580038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of structural valve deterioration and bioprosthetic valve failure utilizing the new European consensus definition in patients undergoing TAVI with first-generation devices: Outcomes beyond 5 years from a single center in Turkey.
    Şentürk B; Dursun H; Çöllüoğlu T; Özdamar H; Ekin T; Tanrıverdi Z; Kaya D
    Anatol J Cardiol; 2021 Aug; 25(8):579-587. PubMed ID: 34369886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Year Outcomes After TAVR With Balloon-Expandable Versus Self-Expanding Valves: Results From the CHOICE Randomized Clinical Trial.
    Abdel-Wahab M; Landt M; Neumann FJ; Massberg S; Frerker C; Kurz T; Kaur J; Toelg R; Sachse S; Jochheim D; Schäfer U; El-Mawardy M; Robinson DR; Richardt G;
    JACC Cardiovasc Interv; 2020 May; 13(9):1071-1082. PubMed ID: 32305398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.